Search Results - "Fleitas Kanonnikoff, T."

NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer by Gambardella, V., Gimeno-Valiente, F., Tarazona, N., Fleitas Kanonnikoff, T., Tolosa, P., Belda Moscardò, M., Garcia-Mico, B., Huerta, M., Roselló, S., Roda, D., Cervantes, A., Castillo, J.

Get full text

RPS6 through the activation of NRF2 causes resistance to antiHER2 drugs in HER2 amplified gastric cancer (GC) models by Gambardella, V., Valiente, F.G., Tarazona, N., Roda, D., Tolosa, P., Fleitas Kanonnikoff, T., Garcia Mico, B., Huerta, M., Rosello, S., Martinez-Ciarpaglini, C., Cervantes, A., Castillo, J.

Get full text

A wind of change in upper gastrointestinal cancers: updates from ESMO 2023 by Cammarota, A., Siebenhüner, A.R., Maqueda, M.A., Fleitas-Kanonnikoff, T., van Laarhoven, H., de la Fouchardière, C., Obermannova, R., Moehler, M., Smyth, E.C.

Get full text

Gastric cancer hospital-based registry: real-world gastric cancer data from Latin America and Europe by Freile, B., van Schooten, T.S., Derks, S., Carneiro, F., Figueiredo, C., Barros, R., Gauna, C., Pereira, R., Romero, M., Riquelme, A., Garrido, M., Owen, G., Ruiz-García, E., Fernández-Figueroa, E.A., Hernández-Guerrero, A., Alsina, M., Viaplana, C., Diez, M., Romero-Alcaide, S., Jiménez-Martí, E., O’Connor, J.M., Cervantes, A., Esteso, F., Fleitas Kanonnikoff, T.

“…Background: Gastric cancer has a high incidence and mortality rate worldwide. Epidemiological, clinical, and molecular features significantly impact patient…”
Get full text

Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables by Ponce Lorenzo, J, Segura Huerta, A, Díaz Beveridge, R, Giménez Ortiz, A, Aparisi Aparisi, F, Fleitas Kanonnikoff, T, Richart Aznar, P, de la Cueva Sapiña, H, Montalar Salcedo, J

“…To identify clinical and biologic variables with significant impact on survival in patients with carcinomas of an unknown primary site (CUP) and to develop a…”
Get full text

P-414 Gastric cancer risk factors knowledge in Mexican population. LEGACy 3A by Ruiz-Garcia, E., Fernandez-Figueroa, E., Avedaño, A. Moreno, Navarrete, U. Coquis, Falcon, J., Manriquez, D. Ramirez, Rios, C. Garcia, Fuentes, S. Velasco, Cardenas-Delgado, I., Takahashi, A. Leon, Diaz, C., Ortiz-Olvera, N., Kanonnikoff, T. Fleitas

Get full text

P-53 A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma by Ku, G., Piha-Paul, S., Gupta, M., Oh, D., Kim, Y., Lee, J., Rha, S., Kang, Y., Díez García, M., Fleitas Kanonnikoff, T., Arrazubi, V., Aviano, K., Demuth, T.

Get full text

O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study by Smyth, E., Mauer, M., Cella, C., Ben-Aharon, I., Piessen, G., Wyrwicz, L., Al-Haidari, G., Kanonnikoff, T. Fleitas, Boige, V., Stahl, M., Martens, U., Obermannová, R., Gomez-Martin, C., Thuss-Patience, P., Arrazubi, V., Avallone, A., Shiu, K., Collienne, M., Giraut, A., Lordick, F.

Get full text

Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos by Ponce Lorenzo, J, Giménez Ortiz, A, Aparisi Aparisi, F, Fleitas Kanonnikoff, T, Montalar Salcedo, J

“…Malignant mesothelioma is an insidious neoplasm arising from the mesotelial surfaces, of the pleural and peritoneal cavities, the tunica vaginalis, or the…”
Get full text

665PNRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer by Gambardella, V, Gimeno-Valiente, F, Tarazona, N, Fleitas Kanonnikoff, T, Tolosa, P, Belda Moscardò, M, Garcia-Mico, B, Huerta, M, Roselló, S, Roda, D, Cervantes, A, Castillo, J

Get full text

100PRPS6 through the activation of NRF2 causes resistance to antiHER2 drugs in HER2 amplified gastric cancer (GC) models by Gambardella, V, Valiente, F G, Tarazona, N, Roda, D, Tolosa, P, Fleitas Kanonnikoff, T, Garcia Mico, B, Huerta, M, Rosello, S, Martinez-Ciarpaglini, C, Cervantes, A, Castillo, J

Get full text

Mesotelioma peritoneal: una presentación clínica inusual en un paciente sin exposición al asbesto by Ponce Lorenzo, J., Giménez Ortiz, A., Aparisi Aparisi, F., Fleitas Kanonnikoff, T., Montalar Salcedo, J.

Get full text

Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond by Jalali, Saba

“…) CRC, highlighting promising data from the CheckMate 8HW and NICHE-2 trials. Tania Fleitas Kanonnikoff from INCLIVA, Hospital…”
Get full text

Mesotelioma peritoneal: una presentación clínica inusual en un paciente sin exposición al asbesto by Ponce Lorenzo, J., Giménez Ortiz, A., Aparisi Aparisi, F., Fleitas Kanonnikoff, T., Montalar Salcedo, J.

“…El mesotelioma maligno es un tumor insidioso que se origina de las superficies mesoteliales de las cavidades pleurales y peritoneales, la túnica vaginal o el…”
Get full text

Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma by Piha-Paul, Sarina A., Gupta, Mukul, Oh, Do-Youn, Kim, Yeul Hong, Rha, Sun Young, Kang, Yoon-Koo, Garcia, Marc Diez, Kanonnikoff, Tania Fleitas, Arrula, Virginia Arrazubi, Aviano, Kayti, Demuth, Tim, Ku, Geoffrey

“…Background: For patients (pts) with HER2-overexpressing metastatic gastric cancer, trastuzumab + chemotherapy +/- pembrolizumab is a standard first-line option…”
Get full text